EDMONTON, Alberta--(BUSINESS WIRE)--March 16, 2006--ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B and C and embolotherapy treatments for tumours, today announced its financial and operational results for the fiscal year ended December 31, 2005.
